期刊文献+

N-{3-氯-4-[(3-氟苄基)氧基]苯基}-6-碘喹唑啉-4-胺的合成工艺改进 被引量:3

Process Improvement on the Synthesis of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-iodoquinazolin-4-amine
下载PDF
导出
摘要 以2-胺基-5-碘苯甲酸为起始原料,经四步反应合成了新型喹唑啉类抗肿瘤药物拉帕替尼的关键中间体——N-{3-氯-4-[(3-氟苄基)氧基]苯基}-6-碘喹唑啉-4-胺,总收率77.9%,其结构经1H NMR和ESI-MS确证。Williamson醚化反应的最佳条件为:4-(6-碘喹唑啉-4-基氨基)-2-氯苯酚(5)30.0 mmol,K2CO324.8 g,18-冠-6 0.79 g,KI 0.49 g,丙酮250 mL,于35℃反应12 h,收率90.1%。 An important intermediate of synthesizing new anti-cancer drugs of quinazoline derivatives,N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-iodoquinazolin-4-amine,was synthesized from 2-amino-5-iodobenzoic acid by a four-step reaction in overall yield of 77.9%.The structure was confirmed by 1H NMR and ESI-MS.The optimum reaction conditions of Williamson reaction at 35 ℃ for 12 h were as follows: 5 was 30 mmol,K2CO3 was 24.8 g,18-crown-6 was 0.79 g,KI was 0.49 g,acetone was 250 mL.The yield was 90.1% under the conditions.
出处 《合成化学》 CAS CSCD 北大核心 2011年第3期421-424,共4页 Chinese Journal of Synthetic Chemistry
基金 天津市自然科学基金资助项目(09JCZDJC21700)
关键词 拉帕替尼 喹唑啉 药物中间体 合成 工艺改进 Lapatinib quinazoline intermediate synthesis process improvement
  • 相关文献

参考文献9

  • 1Petrov K G, Zhang Y M, Carter M, et al. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series[ J]. Bioorg Med Chem Lett ,2006 ,16 :4686 - 4691.
  • 2Carter M, Cockerill G S, Guntrip S B, et al. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors[ P]. WO 99/35 146,1999.
  • 3Priti S H, David R, Melissa B, et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles [ J ]. Mol Cancer Ther,2007,6 : 1629 - 1640.
  • 4Stomiolo A, Rubin P, Magrinat G, et al. A phase I , dose escalation study of lapatinib in combination with carboplatin, paclitaxel, with and without trastuzumab in patients with metastatic breast cancer [ J ]. Cancer Res,2009,69:3121 - 3126.
  • 5Dai C L, Tiwari A K, Wu C P, et al. Lapatinib(Tykerb, GW572016 ) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 [ J ]. Cancer Res ,2008 ,68 :7905 -7914.
  • 6Johnson R L, Farnie G, Clarke R B, et al. Lapatinib selectively inhibits HER2 over-expressing breast cancer stem-like cells [ J]. Cancer Res ,2009,69:5052 - 5055.
  • 7Liu L, Greger J, Shi H, et al. Novel mechanism of lapatinib resistance in HER2-positlve breast tumor cells : Activation of AXL [ J ]. Cancer Res, 2009,69 : 6871 - 6878.
  • 8Cai Z Q, Liu J G, Zhou W W, et al. N-[3-chloro-4- ( 3-fluorobenzyloxy ) -phenyl ] -6-iodoquinazolin-4-amine [ J]. Acta Cryst,2010, E66 : o1810.
  • 9Jin X, Wang W W, Xu G H, et al. Synthesis of lapatinib[ J]. Chinese Journal of Pharmaceuticals ,2009,40 (11) :801 -804.

同被引文献16

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部